Who Owns KalVista Company?

KalVista Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns KalVista Pharmaceuticals?

Understanding KalVista Pharmaceuticals' ownership is key, especially after the FDA approved EKTERLY (sebetralstat) on July 7, 2025. This oral on-demand treatment for hereditary angioedema is their first commercial product, marking a significant moment for the company and HAE patients.

KalVista, founded in 2011, has evolved from its UK origins to a NASDAQ-listed company with a market cap around $640.94 million as of August 15, 2025. Its journey reflects a strategic focus on unmet medical needs, particularly in hereditary angioedema, as detailed in our KalVista PESTEL Analysis.

The ownership structure is a blend of institutional investors, retail shareholders, and insiders, each playing a role in the company's governance and strategic direction.

KalVista Pharmaceuticals was founded in 2011 by Robert Haigh, with Andrew Crockett serving as CEO of the UK subsidiary from its inception. The company's early development was fueled by a focus on small molecule protease inhibitors, driven by a team with expertise in drug discovery.

Founding Vision Established in 2011, the company aimed to innovate in the field of small molecule protease inhibitors. The founding team brought together specialized knowledge in drug discovery and development.	Key Leadership Robert Haigh is recognized as the founder. Andrew Crockett played a crucial early role as CEO of the UK subsidiary, guiding the company from its early stages.	Early Funding Initial growth was supported by venture capital, with the company securing $13.2 million across three funding rounds. This capital was vital for advancing research and development.
Post-IPO Investment A funding round on July 22, 2015, raised $33 million. This event saw participation from significant investors, underscoring early investor confidence.	Notable Early Investors Key early backers included InterWest Partners, Venrock, Vivo Capital, and Novo Holdings. These institutions provided essential capital for the company's progression.	Ownership Structure Genesis While precise founding equity splits are not always public, the initial ownership was shaped by the founders and early venture capital investors who believed in the company's scientific approach.

The early ownership of KalVista Pharmaceuticals was a blend of its founders and the venture capital firms that provided crucial financial backing. While specific percentages of KalVista Pharmaceuticals ownership by individuals at the founding stage are not widely disclosed, the company's trajectory was significantly influenced by these initial stakeholders. The venture capital backing, totaling $13.2 million across early rounds, was instrumental in enabling the company to pursue its research objectives. A notable post-IPO funding round in July 2015, which brought in $33 million, saw participation from prominent investors like InterWest Partners, Venrock, Vivo Capital, and Novo Holdings, further solidifying the investor base and influencing the KalVista company stakeholders. Understanding this early ownership history is key to grasping the KalVista Pharmaceuticals ownership structure as it evolved.

Early Investment Landscape

The initial capital infusion was critical for establishing the company and advancing its scientific pipeline. This early venture capital backing laid the groundwork for future growth and development.

• Founding year: 2011
• Founder: Robert Haigh
• Early CEO (UK subsidiary): Andrew Crockett
• Total early venture capital: $13.2 million
• Post-IPO funding round (July 2015): $33 million

KalVista SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

KalVista Pharmaceuticals, Inc. transitioned to public ownership through its Initial Public Offering (IPO) on April 9, 2015, on the NASDAQ. This event marked a significant shift in its ownership structure, moving from private to public hands and setting the stage for its subsequent market performance and investor base expansion.

The ownership landscape of KalVista Pharmaceuticals is characterized by a substantial presence of institutional investors, who collectively held approximately 61.60% of the company's stock as of July 2025. This significant institutional backing underscores the company's appeal to larger investment entities. Insider ownership stood at around 2.90% as of May 2025, indicating a modest but present stake from those within the company's management and operations. The remaining shares are distributed among public companies and individual investors, contributing to a broad base of KalVista company stakeholders.

Key Institutional Investors in KalVista Pharmaceuticals

Several major institutional investors have established significant positions in KalVista Pharmaceuticals, influencing its strategic direction. These entities play a crucial role in the company's governance and shareholder activities.

• VR Adviser, LLC: 13.42% (March 2025)
• Tang Capital Management LLC: 9.89% (March 2025)
• Frazier Life Sciences Management, L.P.: 9.82% (March 2025)
• Suvretta Capital Management, LLC: 9.84% (March 2025)
• Vestal Point Capital, LP: 9.51% (March 2025)
• SMALLCAP World Fund, Inc.: 6.39% (March 2025)
• Vanguard Index Funds - Vanguard Total Stock Market ETF: 2.81% (May 2025)

The evolution of KalVista Pharmaceuticals' ownership structure has been shaped by key events, including its IPO in 2015 and a notable private placement in 2018 where Merck acquired a 9.9% ownership stake. This strategic investment by Merck not only diversified KalVista's shareholder base but also signaled external confidence in the company's potential. Understanding who owns KalVista and the dynamics of its KalVista Pharmaceuticals ownership history is vital for assessing its trajectory and the influence of its KalVista Pharmaceuticals investors. For a deeper dive into the company's past, a Brief History of KalVista provides valuable context on its development and the forces that have shaped its current ownership status.

KalVista PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The governance of KalVista Pharmaceuticals is overseen by its Board of Directors, comprising William (Bill) Fairey, Benjamin L. Palleiko (also serving as CEO), Brian JG Pereira, MD, Laurence Reid, PhD, Nancy Stuart, Pat Treanor, and Edward W. Unkart. These individuals contribute a range of expertise to guide the company's strategic direction and ensure effective oversight, with some potentially representing significant KalVista company stakeholders.

KalVista Pharmaceuticals operates under a standard one-share-one-vote system for its common stock, meaning each share held corresponds to a single vote on corporate matters. The company does not permit cumulative voting for director elections. Consequently, directors are elected by a simple majority of votes cast in their favor, without provisions for minority KalVista Pharmaceuticals investors to consolidate their votes to elect specific board members. While no specific individuals or entities are publicly noted for possessing disproportionate control through special voting rights, the company's bylaws mandate a supermajority vote of 66 2/3% of the voting stock to remove a director for cause. This provision could offer a degree of protection for minority KalVista Pharmaceuticals shareholders against arbitrary board changes. The collective voting power of executive officers, directors, and principal KalVista Pharmaceuticals investors, if they coordinate their actions, could influence outcomes on matters requiring stockholder approval. There have been no recent public reports indicating proxy contests or significant activist investor campaigns impacting the company's decision-making processes.

Understanding Voting Power at KalVista Pharmaceuticals

The voting structure at KalVista Pharmaceuticals is designed to ensure each share carries equal weight. Understanding this structure is key for KalVista company stakeholders.

• One-share-one-vote principle applies.
• No cumulative voting rights for director elections.
• Director removal requires a 66 2/3% supermajority vote.
• Potential for combined influence among key KalVista Pharmaceuticals stakeholders.
• No recent public reports of proxy battles or activist campaigns.

KalVista Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

KalVista Pharmaceuticals has seen significant shifts in its ownership landscape over the past few years, driven by strategic financial maneuvers and key product developments. The company's public offering in February 2024 was a pivotal moment, raising substantial capital and influencing its shareholder base.

The leadership team, under CEO Ben Palleiko, has navigated the company through critical stages, culminating in the FDA approval of EKTERLY (sebetralstat) on July 7, 2025. This approval marked a significant milestone, leading to strategic licensing agreements that further shape the company's ownership and market presence. An exclusive agreement with Kaken Pharmaceutical for Japan in June 2025, which included an $11 million upfront payment, and a similar deal with Pendopharm for Canada in June 2025, highlight the global commercialization strategy and its impact on stakeholder value.

Licensing Agreements

Exclusive rights for sebetralstat granted to Kaken Pharmaceutical in Japan and Pendopharm in Canada in June 2025. These agreements include upfront payments and potential future royalties.

Insider and Institutional Ownership

Insider holdings saw a slight increase from 2.72% in March 2025 to 2.90% in May 2025. Institutional investors held approximately 61.60% of shares as of July 2025, with 264 institutions owning over 60 million shares by August 15, 2025.

Financial Position

As of April 30, 2025, the company reported $220.6 million in cash, cash equivalents, and marketable securities. This financial strength provides runway into 2027, supporting ongoing operations and strategic initiatives.

Product Approval Impact

The FDA approval of EKTERLY on July 7, 2025, is a landmark achievement. This event is expected to significantly influence KalVista Pharmaceuticals ownership dynamics and investor interest moving forward.

KalVista Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔